27 August 2018 - Xerava achieved high clinical cure rates in clinical trials in patients with cIAI.

Tetraphase Pharmaceuticals today announced that the U.S. FDA has granted approval of Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI). 

In clinical trials, Xerava was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem.

Read Tetraphase Pharmaceuticals press release